Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer

The selective oestrogen receptor (ER) degrader (SERD), fulvestrant, is limited in its use for the treatment of breast cancer (BC) by its poor oral bioavailability. Comparison of the orally bioavailable investigational SERD elacestrant, versus fulvestrant, demonstrates both drugs impact tumour growth...

Descripción completa

Detalles Bibliográficos
Autores principales: Pancholi, Sunil, Simigdala, Nikiana, Ribas, Ricardo, Schuster, Eugene, Leal, Mariana Ferreira, Nikitorowicz-Buniak, Joanna, Rega, Camilla, Bihani, Teeru, Patel, Hitisha, Johnston, Stephen R., Dowsett, Mitch, Martin, Lesley-Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709100/
https://www.ncbi.nlm.nih.gov/pubmed/36446866
http://dx.doi.org/10.1038/s41523-022-00483-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709100/
https://www.ncbi.nlm.nih.gov/pubmed/36446866
http://dx.doi.org/10.1038/s41523-022-00483-1

Ejemplares similares